Simvastatin acts by inhibiting hydroxy-3-methylglutaryl-CoA reductase (HMGCR), thereby lowering cholesterol levels in tumor tissues and reversing the immunosuppressive effects of tumor-infiltrating T cells. This evidence concerns the gene HMGCR and neoplasm.